Lisdexamfetamine in the treatment of methamphetamine dependence: A randomised, placebo‐controlled trial
Addiction · 2025-07 · 120 (7) · 1345-1359
DOI: 10.1111/add.16730 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Addiction, online erschienen am 19.12.2024. Verfasst von Nadine Ezard und 19 weiteren Autor:innen. Beteiligte Einrichtung: National Centre for Clinical Research on Emerging Drugs, University of New South Wales, Sydney, Australia. Hauptthemen laut MEDLINE: Lisdexamfetamine Dimesylate, Amphetamine-Related Disorders, Methamphetamine, Central Nervous System Stimulants. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, St Vincent's Curran Foundation, St Vincent's Health Australia's Inclusive Health Program.
Abstract (Originalsprache)
Aims
This study tested the efficacy and safety of a 12‐week course of lisdexamfetamine in reducing methamphetamine use, an outcome which is associated with improvements in health and wellbeing, in people dependent on methamphetamine. Design, setting and participants This study was a randomised double‐blind placebo‐controlled trial conducted in six specialist outpatient clinics in Adelaide, Melbourne, Newcastle and Sydney, Australia (2018–2021). Participants were164 adults with methamphetamine dependence, reporting at least 14 use days out of the previous 28 days (62% male, 38% female, < 1% other; mean age 39 years).
Interventions
Participants were randomly allocated 1:1 to a 15‐week regimen of lisdexamfetamine (1‐week induction to 250 mg, 12‐week maintenance regimen, 2‐week reduction; n = 80) or matched placebo ( n = 84), followed‐up to Week 19.
Measurements
The primary efficacy measure was past 28‐day methamphetamine use at Week 13. Safety was assessed by adverse event rates. Secondary measures included methamphetamine use during the 12‐week treatment period and treatment satisfaction.
Findings
Nine randomized participants did not start treatment (five were allocated to lisdexamfetamine and four allocated to placebo) and were excluded from the analyses. Fifty‐seven per cent of participants were retained on study medication to primary end‐point. There was only weak evidence of a lisdexamfetamine benefit at 13 weeks [adjusted difference in days of methamphetamine use = 2.2, 95% confidence interval (CI) = –0.5 to 5.0; P = 0.49]. However, throughout the whole 12‐week treatment maintenance phase, the lisdexamfetamine group had fewer days of methamphetamine use in total (difference = 8.8, 95% CI = 2.7–15.0; P = 0.005). The lisdexamfetamine group reported greater self‐reported treatment effectiveness [odds ratio (OR) = 2.89, 95% CI = 1.67–5.02; P < 0.001] and treatment satisfaction (OR = 3.80, 95% CI = 1.93–7.47; P < 0.001). Adverse events with lisdexamfetamine included nausea. Serious adverse events occurred in four (5%) of participants who received lisdexamfetamine.
Conclusions
Lisdexamfetamine appears to reduce methamphetamine use over a 12‐week treatment period, although there is only weak evidence that reduced use is maintained during the last 4 weeks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Centre for Clinical Research on Emerging Drugs, University of New South Wales, Sydney, Australia.
- Alcohol and Drug Service, St Vincent's Hospital Sydney, Sydney, Australia.
- National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia.
- Drug and Alcohol Clinical Research and Improvement Network, NSW Health, Sydney, Australia.
- Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia.
- University of Newcastle, Newcastle, Australia.
ORCID-Profile: Nadine Ezard, Brendan Clifford, Krista J Siefried, Robert Ali, Adrian Dunlop, Rebecca McKetin, Raimondo Bruno, Andrew Carr, James Ward, Michael Farrell, Robert Graham, Paul Haber, Dan Lubman, Mark W Donoghoe, Nick Olsen, Amanda Baker, Michelle Hall, Shalini Arunogiri, Nicholas Lintzeris
Förderung
- National Health and Medical Research Council
- St Vincent's Curran Foundation
- St Vincent's Health Australia's Inclusive Health Program
- National Centre for Clinical Research on Emerging Drugs
- University of New South Wales School of Medicine
- Department of Health, State Government of Victoria
- Edith Collins Centre, Royal Prince Alfred Hospital
Zitieren
APA
Ezard, N., Clifford, B., Siefried, K. J., Ali, R., Dunlop, A., McKetin, R., Bruno, R., Carr, A., Ward, J., Farrell, M., Graham, R., Haber, P., Lubman, D., Donoghoe, M. W., Olsen, N., Baker, A., Hall, M., Arunogiri, S., Lintzeris, N., & LiMA Investigator Group (2025). Lisdexamfetamine in the treatment of methamphetamine dependence: A randomised, placebo‐controlled trial. Addiction, 120(7), 1345-1359. https://doi.org/10.1111/add.16730
Vancouver
Ezard N, Clifford B, Siefried KJ, Ali R, Dunlop A, McKetin R, et al. Lisdexamfetamine in the treatment of methamphetamine dependence: A randomised, placebo‐controlled trial. Addiction. 2025;120(7):1345-1359. doi:10.1111/add.16730
BibTeX
@article{Ezard2025,
author = {Ezard, Nadine and Clifford, Brendan and Siefried, Krista J and Ali, Robert and Dunlop, Adrian and McKetin, Rebecca and Bruno, Raimondo and Carr, Andrew and Ward, James and Farrell, Michael and Graham, Robert and Haber, Paul and Lubman, Dan and Donoghoe, Mark W and Olsen, Nick and Baker, Amanda and Hall, Michelle and Arunogiri, Shalini and Lintzeris, Nicholas and LiMA Investigator Group, LiMA Investigator Group},
title = {Lisdexamfetamine in the treatment of methamphetamine dependence: A randomised, placebo‐controlled trial},
journal = {Addiction},
year = {2025},
volume = {120},
number = {7},
pages = {1345--1359},
doi = {10.1111/add.16730}
}
EUVIMED